Adjunctive Therapies for Community-Acquired Pneumonia

Adrian Ceccato; Miquel Ferrer; Enric Barbeta; Antoni Torres

doi:10.1016/j.ccm.2018.07.008

Adjunctive Therapies for Community-Acquired Pneumonia

Clin Chest Med. 2018 Dec;39(4):753-764. doi: 10.1016/j.ccm.2018.07.008.

Authors

Adrian Ceccato¹, Miquel Ferrer¹, Enric Barbeta¹, Antoni Torres²

Affiliations

¹ Pneumology Department, Respiratory Institute (ICR), Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB), SGR 911 - Ciber de Enfermedades Respiratorias (CIBERES), ICREA Academia, Villarroel 170, Barcelona 08036, Spain.
² Pneumology Department, Respiratory Institute (ICR), Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB), SGR 911 - Ciber de Enfermedades Respiratorias (CIBERES), ICREA Academia, Villarroel 170, Barcelona 08036, Spain; Department of Pneumology, Hospital Clinic of Barcelona, Villarroel 140, Barcelona 08036, Spain. Electronic address: ATORRES@CLINIC.CAT.

PMID: 30390746
DOI: 10.1016/j.ccm.2018.07.008

Abstract

The use of adjuvant therapies for community-acquired pneumonia is still in development. Combinations of antibiotics with macrolides seem to be the best option when there is no risk of resistance. The use of corticosteroids is the treatment of choice in patients with severe pneumonia and a high inflammatory response who do not present contraindications for these drugs. Other drugs await confirmation of their benefit and should be used only on exceptional occasions at this time.

Keywords: Adjunctive treatments; Corticosteroids; Pneumonia.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Combined Modality Therapy / methods*
Community-Acquired Infections / drug therapy*
Community-Acquired Infections / pathology
Humans
Pneumonia / drug therapy*
Pneumonia / pathology